You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
西藏藥業(600211.SH):新活素續約成功 被納入醫保目錄乙類範圍
格隆匯 12-03 16:08

格隆匯12月3日丨西藏藥業(600211.SH)公佈,2021年12月3日,國家醫保局、人力資源社會保障部發布了關於印發《國家基本醫療保險、工傷保險和生育保險藥品目錄》(2021年)的通知,我公司下屬全資子公司成都諾迪康生物製藥有限公司生產的注射用重組人腦利鈉肽(商品名:新活素)續約成功,被納入上述目錄乙類範圍。

新活素醫保支付標準:445元(0.5mg/支),限二級及以上醫療機構用於規範治療效果不佳的急性失代償性心力衰竭短期治療,單次住院支付不超過3天。協議有效期:2022年1月1日至2023年12月31日,有效期滿後按照醫保有關規定調整。

新活素繼2017年、2019年被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》乙類範圍後,此次繼續被納入目錄範圍,醫保支付標準不變。

新活素為公司的主要產品之一,2020年生產量291.14萬支,銷售量262.98萬支,銷售收入9.59億元,佔公司主營業務收入的70.42%;2021年上半年生產量213.35萬支,銷售量223.11萬支,銷售收入8.20億元,佔公司主營業務收入的79.15%。

新活素2017進入基本醫保目錄年來銷量大幅上升。此次續約談判成功,有利於新活素市場份額的擴大、市場佈局的拓展,對公司今後的銷售增長和長遠發展產生積極作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account